Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

291
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
291
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

437
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
437
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

243
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
243
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Social vulnerability and spatial patterns of COVID-19 mortality: Global implications for respiratory health equity.

PloS one·2026
Same author

Comparative Evaluation of DDA- and DIA-Based Proteomic Workflows in Beryllium-Related Lung Disease.

bioRxiv : the preprint server for biology·2026
Same author

Single cell transcriptome signatures and cell-cell interactions associated with sarcoidosis in lung immune cell populations.

Frontiers in immunology·2026
Same author

Reduced CCL/Be-specific CD4+ T cells in CCL3-deficient or peptide-MHC II CAR-T cell-treated mice.

JCI insight·2026
Same author

Immune Regulation by CD55 in Chronic Beryllium Disease.

American journal of respiratory cell and molecular biology·2026
Same author

Molecular characterisation of progressive pulmonary sarcoidosis: protocol for a longitudinal multi-centre study to develop peripheral blood circulating biomarkers for predicting pulmonary sarcoidosis progression.

BMJ open·2026

Related Experiment Video

Updated: Jun 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

Developmental drugs for sarcoidosis.

Ogugua Ndili Obi1, Lesley Ann Saketkoo2, Lisa A Maier3

  • 1Division of Pulmonary Critical Care and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.

Journal of Autoimmunity
|March 28, 2024
PubMed
Summary

Sarcoidosis treatment faces challenges due to limited approved therapies and weak supporting data for steroid-sparing options. This review updates on developmental drugs and novel pathways for sarcoidosis, addressing trial design difficulties.

Keywords:
Anti-inflammatory therapyClinical trialsEfzofitimodHealth-related quality of life (HRQoL)Multi-organMulti-systemNovel therapiesSarcoidosisTherapeutic pathways

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

158

Related Experiment Videos

Last Updated: Jun 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

158

Area of Science:

  • Immunology
  • Pulmonology
  • Rheumatology

Background:

  • Sarcoidosis is a multi-organ granulomatous disease with unknown cause.
  • Over half of patients require treatment, with 10-30% developing chronic progressive disease and pulmonary fibrosis.
  • Current first-line therapy, prednisone, has significant toxicity, and steroid-sparing options lack regulatory approval and robust data.

Purpose of the Study:

  • To provide an update on developmental drugs for sarcoidosis.
  • To outline novel pathways for future drug development.
  • To highlight current clinical trials and discuss challenges in sarcoidosis drug development.

Main Methods:

  • Review of current literature on sarcoidosis treatments.
  • Analysis of developmental drugs and novel therapeutic pathways.
  • Discussion of challenges in clinical trial design for rare diseases.

Main Results:

  • Limited approved treatment options exist for severe, refractory sarcoidosis.
  • There is a critical need for expanded therapeutic strategies and well-conducted clinical trials.
  • Novel pathways for sarcoidosis treatment are being explored.

Conclusions:

  • Developing new treatments for sarcoidosis is essential due to limited options and significant toxicity of current therapies.
  • Addressing challenges in clinical trial design, including patient heterogeneity and outcome measurement, is crucial for advancing sarcoidosis research.
  • Future research should focus on well-designed trials for novel therapeutic targets and existing agents.